Labcorp
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
29% more funds holding in top 10
Funds holding in top 10: 7 [Q3] → 9 (+2) [Q4]
15% more first-time investments, than exits
New positions opened: 105 | Existing positions closed: 91
1.05% more ownership
Funds ownership: 91.88% [Q3] → 92.93% (+1.05%) [Q4]
4% more capital invested
Capital invested by funds: $17.2B [Q3] → $17.8B (+$617M) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 333 | Existing positions reduced: 332
1% less funds holding
Funds holding: 907 [Q3] → 900 (-7) [Q4]
29% less call options, than puts
Call options by funds: $48.5M | Put options by funds: $68.4M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$260
12%
upside
Avg. target
$277
19%
upside
High target
$300
29%
upside
6 analyst ratings
4 positive
67%
2 neutral
33%
0 negative
0%
Citigroup Ralph Giacobbe 0% 1-year accuracy 0 / 1 met price target | 29%upside $300 | Buy Upgraded | 4 Mar 2025 |
Piper Sandler David Westenberg 44% 1-year accuracy 19 / 43 met price target | 12%upside $260 | Neutral Maintained | 10 Feb 2025 |
Barclays Jack Meehan 0 / 0 met price target | 12%upside $260 | Equal-Weight Maintained | 7 Feb 2025 |
Jefferies Tycho Peterson 47% 1-year accuracy 7 / 15 met price target | 25%upside $290 | Buy Maintained | 6 Feb 2025 |
UBS Kevin Caliendo 50% 1-year accuracy 7 / 14 met price target | 23%upside $286 | Buy Maintained | 28 Jan 2025 |
Financial journalist opinion
Based on 6 articles about LH published over the past 30 days
Neutral
PRNewsWire
7 hours ago
Labcorp to Offer HPV and STI Self-Collection Options in Labcorp Patient Service Centers and Participating Physician Offices Nationwide
New offering expands screening options for cervical cancer and sexually transmitted infections (STIs), including chlamydia, gonorrhea, trichomonas or mycoplasma genitalium (Mgen) BURLINGTON, N.C. , April 1, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer nationwide a U.S. Food and Drug Administration (FDA) approved human papillomavirus (HPV) self-collection solution that can help women and their physicians asses the risk of developing cervical cancer.
Neutral
PRNewsWire
23 hours ago
Labcorp to Announce First Quarter Financial Results on April 29, 2025
BURLINGTON, N.C. , March 31, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2025 before the market opens on Tuesday, April 29, 2025.
Positive
Zacks Investment Research
2 weeks ago
Why Labcorp (LH) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Zacks Investment Research
2 weeks ago
Labcorp is Set to Acquire Select Assets of BioReference Health of OPK
LH inks new agreement to acquire BioReference Health's oncology and related clinical testing services businesses.
Neutral
PRNewsWire
3 weeks ago
Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
Transaction to extend Labcorp's leadership in oncology and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 11, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health.
Neutral
Zacks Investment Research
3 weeks ago
Should Labcorp Stock Stay in Your Portfolio Right Now?
LH stays on investors' radar owing to its strong focus on high-growth areas and pursuing strategic acquisitions.
Positive
Zacks Investment Research
1 month ago
Here's Why Labcorp (LH) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Neutral
PRNewsWire
1 month ago
Labcorp Announces Clinical Availability of Liquid Biopsy Test to Guide Personalized Treatment Plans for Patients with Advanced Solid Tumors
Labcorp® Plasma CompleteTM offers oncologists a highly sensitive and specific genomic profiling solution from a simple blood draw BURLINGTON, N.C. , Feb. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the clinical availability of Labcorp® Plasma CompleteTM , a circulating tumor DNA (ctDNA)-based comprehensive genomic profiling solution for patients with advanced solid tumors.
Positive
Seeking Alpha
1 month ago
Labcorp Holdings: Focus On Core Strengths For Future Growth, Initiate At 'Hold'
Labcorp Holdings Inc., a leader in life sciences and diagnostics, is efficiently managing its financials and focusing on core strengths for long-term growth, warranting a “Hold” rating. Competitive advantages include large scale, diversified business model, strong industry relationships, and operational efficiency, driving strong revenue and margin expansion. Recent strategic initiatives like the Fortrea spin-off, Invitae acquisition, and SYNLAB stake enhance Labcorp's core business and future growth prospects.
Positive
Zacks Investment Research
1 month ago
Why Labcorp (LH) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Charts implemented using Lightweight Charts™